Sabine Schmid, M., Lisa Holer, M., Katrin Gysel, M., Kira-Lee Koster, M., Sacha I. Rothschild, M., Laura A. Boos, M., . . . Laetitia A. Mauti, M. Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment. Elsevier.
Chicago Style (17th ed.) CitationSabine Schmid, MD, et al. Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment. Elsevier.
MLA (9th ed.) CitationSabine Schmid, MD, et al. Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment. Elsevier.
Warning: These citations may not always be 100% accurate.